Reckitt & Colman Products Limited

John G Lloyd-Jones

Peter William Dettmar

John W Lewis

A method for the treatment of gastrointestinal disorders associated with Helicobacter pylori infections which comprises administering to a patient an orally effective amount of triclosan is disclosed. The triclosan may be administered in the form of powders, granules, spheroids or liquids, or in unit dosage form as capsules or tablets containing 1 to 100 mg, preferably 10 to 60 mg, of triclosan. The triclosan may also be administered in gastric sustained release medicaments either as raft forming tablets or liquids, optionally to be co-administered with a solid pharmaceutically acceptable carboxylic acid or acid salt, or as mucoadherent-coated granules or spheroids.

Method of treatment of Heliobacter pylori infections with triclosan

A method for the treatment of inflammatory bowel disease which comprises administering to a patient an effective oral or rectal amount of a polyacrylate. There are also described compositions for use in the method.

Use of polyacrylates to reduce proteolytic activity in the human

An analgesic composition in parenteral or sublingual unit dosage form comprising an active dose of buprenorphine and an amount of naltrexone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine.

Analgesic compositions

A method of treating pain which comprises the administration to a patient of a parenterally or sublingually effective dose of buprenorphine together with an amount of naloxone sufficient to prevent substitution in an opiate dependent subject. Preferably when the administration is parenteral the weights of naloxone and buprenorphine are within the ratio of 1:3 to 1:1 and when administered sublingually the weights are within the ratio of 1:2 to 2:1.

Growing community of inventors

Cottingham, United Kingdom

John G Lloyd-Jones